Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Valion Bio, formerly Tivic Health Systems, reports developments tied to its transformation into a biopharmaceutical company focused on innate-immune therapeutics. Company news centers on Entolimod™, a TLR5 agonist lead candidate for acute radiation syndrome, related gastrointestinal radiation-injury work, broader oncology supportive-care applications, and pipeline depth from Entolasta™.
Updates also cover the company’s wholly owned Velocity Bioworks subsidiary, a full-service CDMO providing analytical testing, process development, and cellular and biologic therapy manufacturing services. Recurring announcements include government and public-health preparedness engagement, nonclinical study agreements, financial results, corporate presentations, leadership changes, and the completed name and ticker change from TIVC to VBIO.
Summary not available.
Tivic Health Systems, Inc. (TIVC) reported a strong first quarter 2022 with a 33% increase in net revenue to $428K compared to $323K in Q1 2021. Notably, gross profit surged 219% to $70K, driven by a 77% growth in direct-to-consumer unit sales. Overall unit sales rose by 28%, aided by the termination of less profitable retail arrangements. However, total expenses rose significantly, including $684K in sales and marketing, reflecting increased advertising and e-commerce efforts. Cash reserves stood at approximately $10.8 million as of March 31, 2022.
Jennifer Ernst, CEO of Tivic Health, will speak at FORTUNE Brainstorm Health on May 11, participating in a panel titled Driving Digital Health: Where Wearables Are Headed Next. The event, held in Los Angeles on May 10-11, 2022, focuses on the intersections of health care and technology, highlighting innovations that enhance health outcomes. Ernst's recent accolades include recognition as one of the Inc 100 Female Founders and a leader in Consumer Healthcare.
For more on Tivic Health, visit tivichealth.com.
Tivic Health Systems, Inc. (Nasdaq: TIVC) will report its Q1 2022 financial results on May 16, 2022, at 1:30 pm PT (4:30 pm ET) via conference call and webcast. Investors can access the call at this link. The company focuses on non-invasive bioelectronic treatments for inflammation and related conditions. For further information, visit Tivic Health's website.
Tivic Health® Systems, Inc. (Nasdaq: TIVC) announced its fourth quarter 2021 financial results and year-end shareholder update via conference call on April 19, 2022. The call is scheduled for 2:00 pm PT / 5:00 pm ET, providing insights into the company’s performance in the bioelectronic medicine sector. Interested participants can join by calling the toll-free number 888-506-0062 or the international number 973-528-0011 with the access code 689084. Tivic Health focuses on non-invasive treatments for inflammation and related conditions.
Tivic Health Systems (Nasdaq: TIVC) announced key executive appointments, effective April 1, 2022. Veronica Cai becomes Chief Financial Officer, succeeding Briana Benz. Ryan Sabia is promoted to Chief Operating Officer, and Sanjay Ahuja joins as Senior Vice President, Quality Assurance & Regulatory Affairs. Cai brings 25 years of finance experience, while Ahuja has over 25 years in regulatory affairs. CEO Jennifer Ernst emphasizes that their expertise aligns with the company's growth strategy in bioelectronic medicine.
Summary not available.
Tivic Health (Nasdaq: TIVC), a healthtech company specializing in bioelectronic medicine, was featured in an ABC News story highlighting new bioelectronic technologies for managing conditions like sinus pain and arthritis. ClearUP® Sinus Pain Relief, the only commercially available product showcased, is part of the company's growth strategy following a $17.2 million IPO in November 2021. The company is advancing its Gen2 product and exploring new applications in bioelectronic therapies as alternatives to opioids.
Tivic Health Systems (Nasdaq: TIVC) has launched a 60-person clinical trial to investigate a new bioelectronic device as an alternative to opioids for post-operative care after sinus surgeries. This double-blind study aims to evaluate pain management following functional endoscopic sinus surgery, a common procedure affecting over one million patients annually in the U.S. The company currently offers an FDA-cleared treatment for sinus pain and nasal congestion, seeking to expand its application in pain reduction while minimizing opioid dependence.
Tivic Health Systems, Inc. (NASDAQ: TIVC), a company specializing in non-invasive bioelectronic medicine, has appointed Mindgruve as its digital marketing agency of record. Mindgruve will develop an integrated marketing strategy to enhance brand awareness and optimize e-commerce platforms for Tivic's products, including its FDA-cleared device, ClearUP® Sinus Pain Relief. This partnership aims to capitalize on the growing sinus care market and improve the effectiveness of Tivic's marketing and sales efforts in the U.S.